Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we assessed the influence of the two NCOA3 variants on breast cancer risk by genotyping an Australian case-control study population.
|
21601620 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development.
|
20422428 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
AIB1 is frequently overexpressed in breast cancer and has functions that promote oncogenesis that are independent of estrogen receptor (ER) coactivation.
|
22035181 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since SRC-3 was found to be amplified in breast cancer in 1997, the role of SRC-3 in cancer has been broadly investigated.
|
21647249 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beyond furnishing critical mechanistic insights into SRC-3's involvement in mammary tumor progression, these findings provide opportunities to develop new approaches for breast cancer diagnosis and intervention.
|
21047941 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicate that SRC control of basal and hormone-regulated proliferations is not solely mediated by ERα, and suggest that targeting growth inhibition by disrupting SRC-2 and SRC-3 function may be an effective approach to inhibit the growth of tamoxifen-resistant breast cancer.
|
21059860 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Chromatin immunoprecipitation assays in T-47D human breast cancer cells revealed a TCDD-dependent recruitment of AHR, nuclear co-activator 3 (NCoA3) and the transcription factor forkhead box A1 (FOXA1), a key regulator of breast cancer cell signaling, to CCNG2 resulting in increases in CCNG2 mRNA and protein levels.
|
22596188 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, we found no evidence of association for individuals who carried at least one AIB1 allele of 28 or 29 or more repeat with breast cancer risk.
|
22307791 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study establishes a role for AIB1 in AI-resistant breast cancer and describes a new mechanism of ERα/AIB1 gene regulation which could contribute to the development of an aggressive tumor phenotype.
|
22550166 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells.
|
23660594 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
2,197 breast carcinomas sampled on a pre-existing tissue microarray (TMA) were analyzed for AIB1 expression and amplification by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
|
23322234 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies were included in the meta-analysis if they met all the predetermined criteria, such as: (a) case-control or cohort studies; (b) the primary outcome was clearly defined as BC; (c) the exposure of interest measured was AIB1 polyglutamine repeat length genotype; (d) provided relative risk (RR) or odds ratio (OR) estimates and their 95% confidence intervals (CIs).
|
23483928 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor.
|
23559371 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
|
23230135 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, the effect of AIB1 overexpression on the EMT of the breast cancer cell line T47D was investigated.
|
23762395 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patients with high AIB1 expression (>75%), there was a significant decrease in recurrence rate (HR 0.40, 95% CI 0.26-0.61, P < 0.001) and breast cancer mortality rate (HR 0.38, 95% CI 0.21-0.69, P = 0.0015) with tamoxifen treatment.
|
23670096 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As the members of the p160/nuclear receptor co-activator (NCOA) family, NCOA1, NCOA2 and NCOA3 are known to be overexpressed in breast cancer and essentially involved in estrogen-mediated cancer cell proliferation we asked if these proteins are involved in the ERα-mediated transactivation of PLAC1 in breast cancer cells.
|
24304549 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AIB1 reduction in MCFDCIS cells was correlated with significant reduction in the CD24-/CD44+ breast cancer-initiating cell (BCIC) population, and a decrease in myoepithelial progenitor cells in the DCIS lesions in vitro and in vivo.
|
23851504 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ANCO1 can also repress other E2-responsive genes, indicating that AIB1, AIB1-Δ4 and ANCO1 are important determinants of endocrine and growth factor responsiveness in breast cancer.
|
24678732 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
|
25363551 |
2015 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relationship between the expression of SRC3 and SRC3-pS543, disease-free survival (DFS), and breast cancer specific survival (BCSS) was assessed.
|
26369632 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We show that HER2 signaling promotes breast cancer cell proliferation through regulation of E2F1-driven DNA metabolism and replication genes together with phosphorylation and activity of the transcriptional coactivator SRC-3.
|
26833126 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our results shed light on the molecular mechanisms that regulate AIB1 function in breast cancer.
|
27665502 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of NCOA3 was associated with poor prognosis and higher levels of XBP1-S in breast cancer tissues.
|
27109102 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subsequently, we investigated whether NCOA3 expression was regulated by miRNAs in breast cancer.
|
27831559 |
2016 |